Ranitidine is a histamine H 2 -receptor antagonist, with a potent and long-acting antisecretory effect in humans (1, 2). Previous studies have reported that ranitidine significantly improved the quality of gastric-ulcer healing and histological scores of gastric mucosa in patients with gastric ulcers (3). In addition, ranitidine was successfully utilized in the treatment of active duodenal ulcers and gastric hypersecretions, given that the inhibitory effect of ranitidine on the gastric secretion was much longer than that of cimetidine (4-7). Several studies and discussions at national and international meetings have assessed bioequivalence of ranitidine formulations, using standard methods (8-12). The current work proposed a new modelbased method to solve the same problem.
MATERIALS AND METHODS

Dose
The reference formulation was (Product 1): 300 mg ranitidine tablets (Zantac ® , GlaxoSmithKline, Austria); the test formulation was (Product 2): 300 mg ranitidine tablets (Ranitidine LPH ® S.C. LaborMed Pharma S.A. Romania).
Study design
Twelve healthy Romanian volunteers of both genders (age: 18-55 years, body mass index: 19-25 kg/m 2 ), participated in the current study. The volunteers were within 10% of ideal body weight for height. They were neither nonsmokers, nor alcohol drinkers, nor on regular medication. They denied use of illicit drugs and had no history of liver or kidney disease. The volunteers were instructed to abstain from taking any medication for 1 week prior to and during the study period. They underwent investigations by clinical examinations, clinical laboratory and electrocardiography. Healthy state of the volunteers was judged by means of the investigations performed. Upon completion of clinical examinations, the volunteers were familiarized with all study procedures and written informed consent was obtained from each volunteer.
An open label, double-blind, randomized, crossover design was used (17) (18) (19) (20) (21) (22) . The study followed the tenets of the Declarations of Helsinki promulgated in 1964. It was approved by the Institutional Ethic Committee and Regulatory authorities of Biopharmacy and Pharmacology Research, S.A., Bucharest, Romania.
The 9-day study consisted of two 2-day periods of pharmacokinetic sessions and a one-week wash-out period between doses, to separate treatments. Subjects arrived at the clinical site in the evening (8 p.m.), one day prior to the initiation of the study. After an overnight fast they received the drug (300 mg of ranitidine either in Product 1 or Product 2), with 180 mL of water maintained at room-temperature, at 8 a.m. in the morning.
In each study period, blood samples were withdraw from the forearm vein of the volunteer and were collected by indwelling catheter into heparinized evacuated tubes. The sample preparation procedure was performed according to the following steps: 0.5 mL fresh blood plasma was pipetted out and 50 µL of Internal Standard (Metronidazole 25 µg/mL) was added followed by 100 µL deproteinization agent (perchloric acid 12%), the mixture was vortexed for 30 sec and centrifuged at 4000 rpm for 10 min. An aliquot of this sample (350 µL) was transferred to an autosampler vial, 100 µL of 1M NaHCO 3 was added, the mixture was vortexed for 30 sec and transferred to an autosampler vial; an injection of 100 µL of aliquot sample into the chromatographic system was performed.
The volunteers remained in the clinical site for 24 h after drug administration. They received the standard meal on the first day at 12 a.m. and 5 p.m. Water intake was non-restricted. Other liquids were not allowed. On the second day after blood sampling at 8 a.m., the volunteers left the clinical site and came back for blood sampling every day at 8 a.m. Blood samples were collected before dosing (0.0 h) and then at 0.25, 0.50, 0.75, 1.00, 1.25, 1.50, 1.75, 2.00, 2.50, 3.00, 3.50, 4.00, 5.00, 6.00, 8.00, 10.00, 12.00 and 24.00 h after dosing. Avoidance of alcohol consumption was recommended for the period outside clinic.
Analysis of ranitidine in plasma
The plasma samples were assayed by a validated high-pressure liquid chromatographic (HPLC) method. The stationary phase consisted of octadecyl chemically modified silicagel with particle size 5 µM; 100 Å pore size; fully end-capped. Kromasilâ 100-5C18 (Akzo Nobel) reversed-phase column (15 x 0.46 cm) kept in a thermostat at 45°C was used. The mobile phase consisted of Solvent A (phosphate buffer + 0.2% triethyl amine, pH 4.0) and Solvent B (acetonitrile: methanol in the rate of 1:1) mixture. Both solvents are HPLC grade. Solvent A: Solvent B = 90:10.
The flow rate was 1.0 mL/min. The detection of ranitidine was performed at the wavelength λ = 320 nm. The injection of an aliquot sample into the chromatographic system was automated with an injection volume of 100 µL.
Model construction and validation
The basic set up of a physiologically motivated time-delayed model, analogous to that employed in study (23) , was used. The model was developed using: i) tools of mathematical modeling and analysis based on the linear dynamic system theory, implemented in the software CTDB (Clinical Trials Database) (24, 25) ; ii) the measured plasma concentration-time profiles of ranitidine of the subjects. The optimal model structure was obtained with low range variations of the basic model structures and numbers of parameters and comparing measured concentration-time profiles with modeling results.
The selected scheme of the final optimal model of the pharmacokinetic behavior of ranitidine in the volunteers is shown in Figure 1 . As seen, the scheme consists of three parts. The first part of the scheme contains the subsystem TD that formalizes the time-delayed disposition of ranitidine for absorption (disintegration, dissolution, and multi-fraction gastric emptying). The subsystem TD consists of n, i = 1,…, n, branches, coming from the stomach to the absorption site.
The branch i is characterized by the time-delay parameter τ i and the fraction f i of the ranitidine dose. τ i is the transport time of the fraction f i from the stomach to the absorption site. The subsystem TD is characterized by the mean-time parameter MT td and mean residence time MRT td .
The mean residence time MRT td was calculated using Eq. (1) .
The second part of the scheme contains the subsystem AE (absorption and elimination). The subsystem AE is characterized by the mean-time parameter MT ae . In general, the mean-time parameter MT represents the time constant of the first order system (23) . The third part of the scheme represents EHC. It contains: i) the block with the mean-time parameter MT c , i.e. the mean-time parameter of the EHC; ii) the quantity f c , where f c < 1, i.e. the fraction of the ranitidine dose that undergoes EHC and iii) the time delay τ c of EHC. G 1 stands for the gain of the whole system that is approximated by the developed model. The model structure was described in detail in studies (14, 23) , therefore only a short description of the model is given here.
Bioequivalence testing
A paired Student´s t-test was carried out to compare pharmacokinetic parameters of physiologically motivated time-delayed model and nonmodeling pharmacokinetic parameters (AUC t , AUC, C max , T max ) between reference and test ranitidine formulations. Statistical significance was set at P ≤ 0.05.
Bioequivalence between both formulations was assessed also by Schuirmann´s two one-sided tests approach that is the US Food & Drug Administration's preferred statistical method for evaluating drug-drug interactions (26) . Schuirmann´s two one-sided tests were performed on pharmacokinetic parameters of presented mathematical model and also on AUC t , AUC, C max , T max geometric mean ratios using a 90% confidence interval within the bioequivalence accepted range of 80% to 125%.
RESULTS
To illustrate modeling results, the results obtained for Subject I were arbitrarily chosen as representatives. The plasma concentration-time profile of ranitidine in Subject I after oral administration of 300 mg of ranitidine (the reference product) over the whole time period of the study is depicted in Figure 2 . The plasma concentration-time profile of ranitidine in Subject I after oral administration of 300 mg of ranitidine (the test product) over the whole time period of the study is depicted in Figure 3 . The profile in Figure 3 (the test product) is evidence of similarity with the profile in Figure 2 (the reference product). Figure 4 shows the fraction of ranitidine dose actually present in stomach and predisposed for time-delayed absorption (given in the reference and test formulation). The presented figure illustrates different levels of gastric emptying after administration of the reference/test formulations of ranitidine, confirmed by slight differences in ranitidine dose % actually present in stomach. The pharmacokinetic parameters of physiologically motivated timedelayed model of ranitidine in all subjects enrolled are listed in Tables I and II. Table I : Zantac ® , GlaxoSmithKline, Austria. Table II: Ranitidine LPH ® S.C. LaborMed Pharma S.A. Romania.
Bioequivalence comparison of modeling parameters by Schuirmann´s two one-sided tests approach is shown in Figure 5 . According to the presented test procedures, modeling parameters MRT, n, MRT td , *Q cl , Q cl , MT ae and f c were equivalent by the point esti- MRT -mean residence time of the entire system that formalizes the whole-body disposition behavior of ranitidine; n -number of the fraction of ranitidine dose disposable for absorption; MRT td -mean residence time of the subsystem that formalizes time delayed disposition for absorption; *Q cl -appearent oral clearance estimated using a model that did not incorporate entero-hepatic circulation; Q cl -apparent oral clearance estimated using a model that incorporated entero-hepatic circulation; MT ae -mean time of the subsystems that formalizes absorption and elimination; f c -the fraction of ranitidine dose undergoing entero-hepatic circulation; MT c -mean time of the subsystem that formalizes entero-hepatic circulation; τ c -time delay of the subsystem that formalizes entero-hepatic circulation; a Arithmetic mean. b Standard deviation. MRT -mean residence time of the entire system that formalizes the whole-body disposition behavior of ranitidine; n -number of the fraction of ranitidine dose disposable for absorption; MRT td -mean residence time of the subsystem that formalizes time delayed disposition for absorption; * Q cl -appearent oral clearance estimated using a model that did not incorporate entero-hepatic circulation; Q cl -apparent oral clearance estimated using a model that incorporated entero-hepatic circulation; MT ae -mean time of the subsystems that formalizes absorption and elimination; f c -the fraction of ranitidine dose undergoing entero-hepatic circulation; MT c -mean time of the subsystem that formalizes entero-hepatic circulation; τ c -time delay of the subsystem that formalizes entero-hepatic circulation; a Arithmetic mean. Figure 5 ). Among the modeling parameters, Schuirmann´s two one-sided tests revealed equivalence only for the parameters of MRT and n with respect to the point estimate and 90% confidence interval.
Nonmodeling pharmacokinetic parameters AUC t , AUC, C max and T max listed in Table III (ranitidine reference formulation) and Table IV (ranitidine test formulation) were also compared by Schuirmann´s two one-sided tests (26) . The point estimates and the 90% confidence limits for AUC t , AUC, C max and T max are shown in Figure 6 AUC t -area under the plasma concentration-time curve calculated from the measured levels, from time zero to the time of last quantifiable level; AUCarea under the plasma concentration-time curve extrapolated to infinity; C max -maximum plasma concentration; T max -time to peak plasma concentration; a Arithmetic mean. b Standard deviation. (Figure 6 ). Thus, in terms of the presented nonmodeling parameters, Schuirmann´s two one-sided tests approach delineate bioequivalence between the two ranitidine formulations with respect to their point estimates.
DISCUSSION
The relative bioavailability of ranitidine administered as a single 300 mg oral dose of two formulations: Zantac ® , GlaxoSmithKline, Austria, (reference formulation), and Ranitidine LPH ® , S.C. LaborMed Pharma S.A. Romania, (test formulation), were evaluated under fasting conditions, using a two-way crossover study with 12 Romanian volunteers.
Application of physiologically motivated time-delayed model on bioequivalence assessment of piroxicam was a first report in this field (23) . Analogus to this study, our work aimed at comparing the pharmacokinetic parameters using the physiologically motivated time-delayed model to assess bioequivalence of ranitidine.
From the viewpoint of the paired Student´s t-test, no significant statistical differences in the parameters of the physiologically motivated time-delayed model and at AUC t , AUC, C max and T max between reference (Zantac ® , GlaxoSmithKline, Austria) and test formulations (S.C. LaborMed Pharma S.A. Romania, generic formulation) of ranitidine were observed. We confirm similarities in the gastric emptying processes, after administration of the reference and generic ranitidine formulations as evident in Figure 4 and therefore a bioequivalence of observed ranitidine formulations.
However, Schuirmann´s two one-sided tests approach also assessed bioequivalence between reference and test ranitidine formulations: from the viewpoint of point estimate, most of the modeling parameters (MRT, n, MRT td , *Q cl , Q cl , MT ae and f c ) and all nonmodeling parameters (AUC t , AUC, C max and T max ) of reference and test ranitidine formulations were equivalent. Schuirmann´s two one-sided tests pointed to non-bioequivalence only for the parameters τ c and MT c (26) .
Regarding the 90% confidence interval falling within the bioequivalence acceptable range of 80-125%, this was reported only for the parameters of physiologically motivated time-delayed model MRT and n, while confidence limits for the other modeling/nonmodeling parameters did not fall within the bioequivalence acceptable range. Results from the Schuirmann´s two one-sided tests approach therefore indicated total bioequivalence between reference and test formulation of ranitidine only for the significant modeling parameters MRT and n.
According to previous studies, piroxicam, just like ranitidine, is known as a drug with EHC (27-31, 14, 32) . Figures 2 and 3 however confirm that ranitidine does not have similar long elimination time in humans as stated for piroxicam (23, (32) (33) (34) .
Tables I-II express the significant pharmacokinetic parameters of our physiologically motivated time-delayed model used for the bioequivalence assessment of ranitidine. In terms of EHC, the most distinct, presented parameters are the time delay τ c , the fraction f c and the mean time MT c . The ranitidine fraction dose undergoing EHC was observed within the range 9-71%. The time delay of the ranitidine subsystem that formalized EHC was also considerably wide-ranging (from 0.33h to 5.92h), analogous to the mean time MT c (from 0.05h to 3.76h). The whole-body disposition behavior of ranitidine expressed by parameters MRT was within the range from 3.71h to 6.65h. The large range of observed pharmacokinetic parameter values recorded in Tables I-II , confirmed substantial differences between the gastric emptying processes after administration of the reference and generic formulation of ranitidine, in individual subjects.
Both ranitidine formulations were well tolerated by volunteers. Unexpected incidents that could have influenced the results did not occur. All volunteers participated in the bioequivalence study and continued till the end. No serious adverse event was found during this study.
To conclude, this study aimed for the bioequivalence assessment of ranitidine by using a physiologically motivated time-delay model and Schuirmann´s two one-sided tests procedure. Pursuant to comparisons of modeling approach results with results from determing the 90% confidence intervals of the geometric mean AUC t , AUC, C max and T max ratios the total non-equivalence at parameters MT c and τ c by Schuirmann´s two one-sided tests has been recorded. The most non-bioequivalence of ranitidine was thus probably due to processes of ranitidine entero-hepatic circulation. Following this study one of the reasons of a width range of the entero-hepatic circulation parameters is intra-individual variability of tested subjects.
The assay results of this study indicated that presented physiologically motivated time-delayed model can be useful as an additional tool for determining drug bioequivalence assessment, especially from the viewpoints of finding and identifying parameters causative of non-bioequivalence between drug formulations.
